COMPANY

Neurona Therapeutics

HQ: South San Francisco, CA source · neuronatherapeutics.com ↗ · West Coast

Keywords: cell therapy neurology focal epilepsy regenerative medicine Mesial Temporal Lobe Epilepsy Temporal Lobe Epilepsy NRTX-1001

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Undisclosed round · $120M · announced Feb 8, 2024 Company release ↗
Source quote
- Feb 8, 2024 · Company release ↗
  “Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders – The financing”

Raises announced in these releases: $120M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Nov 14, 2024 Trial start 1: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) source ↗
Feb 8, 2024 Raise Undisclosed round · $120M source ↗
Jun 16, 2022 Trial start Phase 3: Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) source ↗

Jun 15, 2027 (ESTIMATED) · 1 · A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) · NCT06422923
2029-02 (ESTIMATED) · Phase 3 · Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) · NCT05135091

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05135091	Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))	Phase 3	Recruiting	Jun 16, 2022	2029-02 (estimated)
NCT06422923	A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)	1	Recruiting	Nov 14, 2024	Jun 15, 2027 (estimated)